CREO vs. EKF, NCYT, NIOX, MXCT, ANCR, AGY, 4BB, FUM, KOO, and AVCT
Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Novacyt (NCYT), NIOX Group (NIOX), MaxCyte (MXCT), Animalcare Group (ANCR), Allergy Therapeutics (AGY), 4basebio (4BB), Futura Medical (FUM), Kooth (KOO), and Avacta Group (AVCT). These companies are all part of the "medical" sector.
Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.
In the previous week, Creo Medical Group had 2 more articles in the media than EKF Diagnostics. MarketBeat recorded 4 mentions for Creo Medical Group and 2 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 1.23 beat Creo Medical Group's score of 0.52 indicating that EKF Diagnostics is being referred to more favorably in the news media.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
43.0% of Creo Medical Group shares are held by institutional investors. Comparatively, 71.4% of EKF Diagnostics shares are held by institutional investors. 20.7% of Creo Medical Group shares are held by company insiders. Comparatively, 5.1% of EKF Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
EKF Diagnostics has a net margin of 4.47% compared to Creo Medical Group's net margin of -85.54%. EKF Diagnostics' return on equity of 3.83% beat Creo Medical Group's return on equity.
Creo Medical Group has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Summary
EKF Diagnostics beats Creo Medical Group on 11 of the 15 factors compared between the two stocks.
Get Creo Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creo Medical Group Competitors List
Related Companies and Tools
